Get the Stockscreener App
0.2716
1.24%
-0.0034
After Hours:
.28
0.0084
+3.09%
Biodesix Inc stock is traded at $0.2716, with a volume of 505.38K.
It is down -1.24% in the last 24 hours and down -9.65% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
See More
Previous Close:
$0.275
Open:
$0.2873
24h Volume:
505.38K
Relative Volume:
0.07
Market Cap:
$46.84M
Revenue:
$49.09M
Net Income/Loss:
$-52.15M
P/E Ratio:
-0.4178
EPS:
-0.65
Net Cash Flow:
$-45.93M
1W Performance:
-1.84%
1M Performance:
-9.65%
6M Performance:
-81.65%
1Y Performance:
-83.02%
1-Day Range:
$0.27
$0.29
1-Week Range:
$0.2503
$0.305
52-Week Range:
$0.1718
$2.04
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.2716 | 46.84M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
429.33 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.20 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
547.01 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.38 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.24 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 127.0% in May - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company - simplywall.st
Millennium Management LLC Buys 33,329 Shares of Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix (BDSX) Partners with APAPP to Enhance Lung Cancer Care - GuruFocus
Biodesix, Inc. Partners with Association of Pulmonary Advanced Practice Providers to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs - MarketScreener
Biodesix Partners with Association of Pulmonary Advanced Practic - GuruFocus
Biodesix partners with Association of Pulmonary APPs for lung cancer education - TipRanks
Public market insider buying at Freehold Royalties (FRU) - The Globe and Mail
Biodesix Partners with Association of Pulmonary Advanced - GlobeNewswire
Biodesix Partners with APAPP to Enhance Lung Cancer Education and Access to Diagnostic Tools - Nasdaq
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs - Yahoo
Jane Street Group LLC Acquires New Holdings in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Wall Street’s big rally stalls following some discouraging economic data - The Globe and Mail
Biodesix at 45th Annual William Blair Growth Stock Conference: Lung Health Focus - Investing.com Canada
Northern Trust Corp Grows Stake in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - The Manila Times
Scotiabank Has Lowered Expectations for Biodesix (NASDAQ:BDSX) Stock Price - Defense World
Biodesix Announces New Data on the VeriStrat® Test to be Present - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Independent Director of Biodesix Picks Up 15% More Stock - Yahoo Finance
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut - MSN
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX Stock News - GuruFocus
Biodesix price target lowered to $2 from $3 at Scotiabank - TipRanks
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
What's Behind The Big Stock Moves? BDSX, APLM, RNAZ... - Nasdaq
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
William Blair Has Bearish Estimate for Biodesix Q2 Earnings - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biodesix Inc Stock (BDSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHULER JACK W | Director |
May 19 '25 |
Buy |
0.34 |
723,239 |
246,624 |
20,918,174 |
| Vazquez Chris | Chief Accounting Officer |
May 12 '25 |
Sale |
0.36 |
112 |
40 |
18,113 |
| Vazquez Chris | Chief Accounting Officer |
May 13 '25 |
Sale |
0.35 |
112 |
40 |
18,001 |
| Pestano Gary Anthony | Chief Development Officer |
May 12 '25 |
Sale |
0.36 |
223 |
80 |
157,163 |
| Pestano Gary Anthony | Chief Development Officer |
May 13 '25 |
Sale |
0.35 |
222 |
78 |
156,941 |
| O'Kane Kieran | Chief Commercial Officer |
May 12 '25 |
Sale |
0.36 |
239 |
86 |
139,290 |
| O'Kane Kieran | Chief Commercial Officer |
May 13 '25 |
Sale |
0.35 |
238 |
84 |
139,052 |
| Hutton Scott | President & CEO |
May 12 '25 |
Sale |
0.36 |
1,888 |
679 |
722,271 |
| Hutton Scott | President & CEO |
May 13 '25 |
Sale |
0.35 |
1,887 |
666 |
720,384 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
May 12 '25 |
Sale |
0.36 |
496 |
178 |
249,121 |
0.18%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):